Tenaya Therapeutics, Inc.
Tenaya Therapeutics (NASDAQ:TNYA) said it plans Q4 updates for gene therapy TN-401 in PKP2-associated ARVC, with early data showing ~60% to 67% PVC reductions across patients (up to 52 weeks). It also reported Phase 1 results for TN-301 (72 patients) and Phase 2-enabling work. Tenaya had ~$78M cash and a $10M upfront Alnylam deal.
Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements
Tenaya Therapeutics (NASDAQ: TNYA) said it granted inducement stock options to its new CFO Eric Hyllengren for 1,650,000 shares and options totaling 187,200 shares to two new non-executive employees. The options’ exercise price is $0.8365, matching July 13, 2026’s close, with a 10-year term and 4-year vesting.
Over the past 7 days, alphai's AI scored 1 news story mentioning TNYA (Tenaya Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TNYA coverage spans financial news, technology and corporate actions.
In the last 30 days, TNYA insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($21K). The most active reporter was Tingley Whittemore, Chief Medical Officer, with 4 filings.
Q4 regulatory update and durability plans for TN-401 are the near-term catalysts, with TN-301 Phase 2 plans as the secondary timeline.
Positive interim gene-therapy readouts and a $10M Alnylam upfront extend runway, but near-term valuation remains highly dependent on late-stage pivotal trial alignment.
This is a routine equity-grant disclosure tied to new hires, with limited direct signal on near-term fundamentals.
Lease termination reduces fixed facility exposure but adds one-time costs (forfeited deposit and termination fee) and signals manufacturing footprint change.
CFO transition is a near-term governance/operations catalyst; the disclosed equity/comp terms can affect sentiment but not fundamentals immediately.
alphai scores every news story that mentions TNYA with an AI model for sentiment and relevance, and aggregates insider trades from Tenaya Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tenaya Therapeutics (NASDAQ:TNYA) said it plans Q4 updates for gene therapy TN-401 in PKP2-associated ARVC, with early data showing ~60% to 67% PVC reductions across patients (up to 52 weeks). It also reported Phase 1 results for TN-301 (72 patients) and Phase 2-enabling work. Tenaya had ~$78M cash and a $10M upfront Alnylam deal.
5 min readTenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements
6 min readTenaya Therapeutics (NASDAQ: TNYA) said it granted inducement stock options to its new CFO Eric Hyllengren for 1,650,000 shares and options totaling 187,200 shares to two new non-executive employees. The options’ exercise price is $0.8365, matching July 13, 2026’s close, with a 10-year term and 4-year vesting.
2 min readTenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. 8-K 0001858848 false 0001858848 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
4 min readTenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001858848 false 0001858848 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
4 min readTenaya Therapeutics reported interim MyPEAK-1 Phase 1b/2 data for TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. As of a May 2026 cutoff, six evaluable patients showed improvements in echocardiographic hypertrophy and symptom measures; three improved exercise capacity. Company said benefits were sustained up to two years in Cohort 1 and earlier in Cohort 2. PRIME and FDA rare disease processes apply.
4 min readTenaya Therapeutics CEO Ali Faraz sold 3,390 shares of common stock at $0.7934 per share on May 18, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. After this transaction, Faraz directly holds 440,014 shares, which includes 321,581 shares that will be issued upon future RSU vesting. This sale is identified as being for tax purposes rather than a reduction in long-term holdings.
2 min readTenaya Therapeutics announced promising interim results from its RIDGE-1 Phase 1b/2 trial for TN-401, an investigational gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The trial data, presented at #ASGCT, showed consistent reductions in arrhythmias among adult patients. This development highlights ongoing progress in addressing inherited arrhythmia syndromes and follows previous announcements about presenting clinical data and honoring contributions to hypertrophic cardiomyopathy research.
3 min readTenaya Therapeutics released interim results from its RIDGE™-1 Phase 1b/2 clinical trial for TN-401 gene therapy, targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The study showed that all patients experienced significant reductions (mean 64%) in daily premature ventricular contractions (PVCs), and the treatment was well tolerated. The European Medicines Agency also granted TN-401 PRIME designation, recognizing its potential to address unmet medical needs.
4 min readTenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), matching the consensus estimate. CEO Faraz Ali highlighted clinical progress in 2025 and anticipates further updates in the first half of 2026 for its gene therapy programs TN-201 and TN-401. The company also presented positive preclinical data for its HDAC6 inhibitor, TN-301, showing improvements in Duchenne muscular dystrophy models.
3 min read
